Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (778)	12/28/1999 9:34:00 PM
From: Biotech Jim	Respond to of 3158

I agree completely with your thoughts as to why there were few buyouts of the 2nd or 3rd tiers. They have to want to be taken out. However, "Same with SNAP, from another point of view --- decent cash and no big clinical trial drain on cash." As to the latter thought about the lack of clinical trials, I would think that therein lies the problem as to why there has not been much price appreciation as well as their burn. Great molecular biology, but their collaborations seem not to get renewed. BJ

To: tommysdad who wrote (778)	12/28/1999 10:01:00 PM
From: LLCF	Read Replies (1) \| Respond to of 3158

<Most biotechs have "shareholder rights" plans in place> Interesting... do NBIX,ABSC,ABGX,PDLI,PCYC,GLGC,CORR,CEPH,BTRN or INCY have them? Also, if MEDI had bid $6 for BTRN when it was trading @ $3, wouldn't the shareholders decide weather to sell [assuming a shareholders rights plan in effect]... ie. nothing would be 'triggered' unless stock was 'accumulated' in a hostile manner would it? How much higher do you think the average price for the above names would be today in a buyout vs 6 months ago? DAK